![conference banner](/images/conference-banner.jpeg)
Abstract
Mammalian sirtuins (SIRT1-7) are NAD+-dependent deacetylases, which play an important role in aging and in a wide range of cellular functions. SIRT1, the best-characterized member of the family, acts as a sensor of the redox state and triggers in the cell the appropriate defense response. A large body of evidence has showed that SIRT1 induces both cellular and systemic protective effects in the cardiovascular system by preventing stress-induced apoptosis and senescence, and mitigating endothelial dysfunction. Hence, SIRT1 is now foreseen as a potential therapeutic target for a growing number of cardiovascular diseases. Recently, it has been suggested that SIRT1 activation could also be considered as a neuroprotective strategy. Indeed, SIRT1 protects against ischemia/reperfusion injury both in vitro and in vivo and avoids severe ischemic damage by preserving cerebral blood flow. In the last years it was suggested that others sirtuins, in particular SIRT3 and SIRT6, could exert beneficial effects in vascular syndromes. The aim of this review was to describe and discuss recent experimental evidence on the effects of SIRT1 and other sirtuins on the pathophysiology of cardio- and cerebrovascular diseases, underlying a potential therapeutic effect of these enzymes in the treatment and/or prevention of such conditions.
Keywords: SIRT1, SIRT3, SIRT6, drugs, vascular function.
Current Drug Targets
Title:Sirtuins: Possible Clinical Implications in Cardio and Cerebrovascular Diseases
Volume: 18 Issue: 4
Author(s): Valeria Conti, Maurizio Forte, Graziamaria Corbi, Giusy Russomanno, Luigi Formisano, Alessandro Landolfi, Viviana Izzo, Amelia Filippelli, Carmine Vecchione and Albino Carrizzo
Affiliation:
Keywords: SIRT1, SIRT3, SIRT6, drugs, vascular function.
Abstract: Mammalian sirtuins (SIRT1-7) are NAD+-dependent deacetylases, which play an important role in aging and in a wide range of cellular functions. SIRT1, the best-characterized member of the family, acts as a sensor of the redox state and triggers in the cell the appropriate defense response. A large body of evidence has showed that SIRT1 induces both cellular and systemic protective effects in the cardiovascular system by preventing stress-induced apoptosis and senescence, and mitigating endothelial dysfunction. Hence, SIRT1 is now foreseen as a potential therapeutic target for a growing number of cardiovascular diseases. Recently, it has been suggested that SIRT1 activation could also be considered as a neuroprotective strategy. Indeed, SIRT1 protects against ischemia/reperfusion injury both in vitro and in vivo and avoids severe ischemic damage by preserving cerebral blood flow. In the last years it was suggested that others sirtuins, in particular SIRT3 and SIRT6, could exert beneficial effects in vascular syndromes. The aim of this review was to describe and discuss recent experimental evidence on the effects of SIRT1 and other sirtuins on the pathophysiology of cardio- and cerebrovascular diseases, underlying a potential therapeutic effect of these enzymes in the treatment and/or prevention of such conditions.
Export Options
About this article
Cite this article as:
Conti Valeria, Forte Maurizio, Corbi Graziamaria, Russomanno Giusy, Formisano Luigi, Landolfi Alessandro, Izzo Viviana, Filippelli Amelia, Vecchione Carmine and Carrizzo Albino, Sirtuins: Possible Clinical Implications in Cardio and Cerebrovascular Diseases, Current Drug Targets 2017; 18 (4) . https://dx.doi.org/10.2174/1389450116666151019095903
DOI https://dx.doi.org/10.2174/1389450116666151019095903 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response, and/or therapy ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The No-Reflow Phenomenon in the Coronary Circulation
Cardiovascular & Hematological Agents in Medicinal Chemistry PI-3 Kinase-PTEN Signaling Node: An Intercept Point for the Control of Angiogenesis
Current Pharmaceutical Design Low-dose Tissue Plasminogen Activator is as Effective as Standard Tissue Plasminogen Activator Administration for the Treatment of Acute Ischemic Stroke
Current Neurovascular Research Glucagon-Like Peptide 1 and the Cardiovascular System
Current Diabetes Reviews Attenuation of Cardiac Ischaemia-reperfusion Injury by Treatment with Hydrogen-rich Water
Current Molecular Medicine Betulinic Acid as a Potent and Complex Antitumor Phytochemical: A Minireview
Anti-Cancer Agents in Medicinal Chemistry Inflammation in Atherosclerosis: A New Therapeutic Target
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Immunologic Modulations to Enhance Post-Stroke Recovery
Current Immunology Reviews (Discontinued) The Effect of Statins on the Differentiation and Function of Central Nervous System Cells
Current Medicinal Chemistry G Protein Coupled Receptors - In Silico Drug Discovery and Design
Current Topics in Medicinal Chemistry Targeting NO/cGMP Signaling in the CNS for Neurodegeneration and Alzheimer’s Disease
Current Medicinal Chemistry Spinal Cord Injury Changes Cytokine Transport
CNS & Neurological Disorders - Drug Targets Cardioprotection Against Ischemia/Reperfusion Injury and Chromogranin ADerived Peptides
Current Medicinal Chemistry Ranolazine and its Antiarrhythmic Actions
Cardiovascular & Hematological Agents in Medicinal Chemistry Kidney Injury Molcule-1 in Acute and Chronic Kidney Disease
Recent Patents on Biomarkers Prevention of Oxidative Stress and Diseases by Antioxidant Supplementation
Medicinal Chemistry Structural Diversity of Neuritogenic Substances and their Application Perspective
Mini-Reviews in Medicinal Chemistry Protective Effects of Anesthetics on Vascular Function Related to K<sup>+</sup> Channels
Current Pharmaceutical Design Inflammatory Modulation of Hepatocyte Apoptosis by Nitric Oxide: In Vivo, In Vitro, and In Silico Studies
Current Molecular Medicine Inotropic Therapies in Asphyxiated Neonates: The Clinical and Laboratory Facts
Current Pediatric Reviews